key: cord-0783253-h4e7nwh5
authors: Adhikari, Anurag; Abayasingam, Arunasingam; Rodrigo, Chaturaka; Agapiou, David; Pandzic, Elvis; Brasher, Nicholas A; Madushan Fernando, Bentotage Samitha; Keoshkerian, Elizabeth; Li, Hui; Kim, Ha Na; Lord, Megan; Popovic, Gordona; Rawlinson, William; Mina, Michael; Post, Jeffrey J; Hudson, Bernard; Gilroy, Nicole; Bartlett, Adam W.; Ahlenstiel, Golo; Grubor-Bauk, Branka; Dwyer, Dominic; Konecny, Pamela; Lloyd, Andrew R; Martinello, Marianne; Bull, Rowena A; Tedla, Nicodemus
title: Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection
date: 2021-12-22
journal: bioRxiv
DOI: 10.1101/2021.12.21.473774
sha: c5d18f430357610b04faa824a0115704d7c29e5f
doc_id: 783253
cord_uid: h4e7nwh5

Phagocytic responses by effector cells to antibody or complement-opsonised viruses have been recognized to play a key role in anti-viral immunity. These include antibody dependent cellular phagocytosis mediated via Fc-receptors, phagocytosis mediated by classically activated complement-fixing IgM or IgG1 antibodies and antibody independent phagocytosis mediated via direct opsonisation of viruses by complement products activated via the mannose-binding lectin pathway. Limited data suggest these phagocytic responses by effector cells may contribute to the immunological and inflammatory responses in SARS-CoV-2 infection, however, their development and clinical significance remain to be fully elucidated. In this cohort of 62 patients, acutely ill individuals were shown to mount phagocytic responses to autologous plasma-opsonised SARS-CoV-2 Spike protein-coated microbeads as early as 10 days post symptom onset. Heat inactivation of the plasma prior to use as an opsonin caused 77-95% abrogation of the phagocytic response, and pre-blocking of Fc-receptors on the effector cells showed only 18-60% inhibition. These results suggest that SARS-CoV-2 can provoke early phagocytosis, which is primarily driven by heat labile components, likely activated complements, with variable contribution from anti-Spike antibodies. During convalescence, phagocytic responses correlated significantly with anti-Spike IgG titers. Older patients and patients with severe disease had significantly higher phagocytosis and neutralisation functions when compared to younger patients or patients with asymptomatic, mild, or moderate disease. A longitudinal study of a subset of these patients over 12 months showed preservation of phagocytic and neutralisation functions in all patients, despite a drop in the endpoint antibody titers by more than 90%. Interestingly, surface plasmon resonance showed a significant increase in the affinity of the anti-Spike antibodies over time correlating with the maintenance of both the phagocytic and neutralisation functions suggesting that improvement in the antibody quality over the 12 months contributed to the retention of effector functions. Author Summary Limited data suggest antibody dependent effector functions including phagocytosis may contribute to the immunological and inflammatory responses in SARS CoV-2 infection, however, their development, maintenance, and clinical significance remain unknown. In this study we show: Patients with acute SARS CoV-2 infection can mount phagocytic responses as early as 10 days post symptom onset and these responses were primarily driven by heat labile components of the autologous plasma. These results indicate that the current approach of studying phagocytosis using purified or monoclonal antibodies does not recapitulate contribution by all components in the plasma. In convalescent patients, high phagocytic responses significantly correlated with increasing age, increasing disease severity, high neutralisation functions and high anti-Spike antibody titers, particularly IgG1. Longitudinal study of convalescent patients over a 12-month period showed maintenance of phagocytic and neutralisation functions, despite a drop in the anti-Spike endpoint antibody titers by more than 90%. However, we found significant increase in the affinity of the anti-Spike antibodies over the 12-month period and these correlated with the maintenance of functions suggesting that improvement in the antibody quality over time contributed to the retention of effector functions. Clinically, measuring antibody titers in sera but not the quality of antibodies is considered a gold standard indicator of immune protection following SARS-CoV 2 infection or vaccination. Our results challenge this notion and recommends change in the current clinical practice.

). At the time of collection of the 12-month samples, Australia had limited 133 community transmission following the first wave in 2020 when these participants were infected [19] .

134 Although the specific SARS-CoV-2 variants in these patients were not genotyped, all predate infections 219 positively with most independent variables, whereas age and DPS associated negatively or poorly with 220 other variables (Fig 4) .

221 

A parameter Spearman's covariance matrix to plots the associative relationship between the independent variable using the standardized beta coefficient covariance scale (range -1 to +1), where the score above one is considered a positive relationship, zero as no relationship and less than one as negative relationship. Table 2 ). Table 2 ). 

Plasma from all six acutely ill participants demonstrated detectable phagocytosis of microbeads coated 139 with SARS-CoV-2 Spike protein as early as 10 days post symptom onset regardless of disease severity, 140 and despite 2/6 having no detectable anti-Spike antibody end point titers

The gating strategy used to determine the proportion of positive cells and their mean fluorescence 142 intensity (MFI), as well as microscopic validation for intracellular uptake of the opsonised microbeads 143 is presented in Supplementary Fig 1

Although the number of 148 the acutely ill patients is limited, those with high Spike p-scores had low viral loads, whereas individuals 149 with low p-scores had relatively high viral loads (Fig 1B). However, there was no correlation between 150 the anti-Spike EPTs and Spike p-scores (Spearman's r = 0.8, p = 0.07, Fig 1C), suggesting contribution 151 from other components of the plasma including the heat labile complements. To confirm this, plasma 152 from these patients was heat inactivated prior to use as an opsonin and found a profound abrogation of 153 phagocytosis by 77-95% in 5/6 of patients

Measurement of anti-SARS-CoV-2 antibody EPT in sera collected during convalescence in the 10-165 99 DPS window (n=56) showed that 100% had detectable anti-Spike IgG and 98% had

Further analysis of the IgG subclasses of the anti-Spike responses 167 showed that the antibodies were primarily IgG1 and IgG3 subtypes

There was also variable levels of anti-Spike IgA and IgM antibodies (Fig 2C). Functionally

/56) of all patient samples demonstrated significant phagocytosis of Spike protein-coated microbeads 170 (Fig 2D), 84% (47/56) had phagocytosis of RBD protein-coated microbeads, albeit at lower phagocytic 171 scores (Fig 2E), and 86% (48/56) could neutralise Spike pseudovirus

moderate (n=17) or severe 173 (n=18) disease showed a severity dependent increase in anti-Spike antibody EPTs (Figs 2A and 2C)

Multiple comparison of the anti-Spike antibody 179 subtypes among disease severity groups showed higher anti-Spike IgG1 (Kruskal-Wallis test, mild versus 180 severe: p = 0.04 and moderate versus severe: p = 0.03), whereas difference between other subtypes were 181 not statistically significant (Fig 2C). There was also a significant difference in Spike p-scores between 182 the disease severity groups

03) and mild disease groups (mean difference = -650.6, 95% CI = -1088 to 185 -213.3, p = 0.001) (Fig 2D). Similarly, a significant difference in RBD p-scores was evident between 186 severe and mild disease groups (Kruskal-Wallis test, p = 0.04) (Fig 2E). The neutralisation titers were 187 also significantly different between disease severity groups

Age dependent differences in phagocytosis, endpoint antibody titers and neutralisation function at 192 convalescence 193 Analysis of the age stratified groups: >60 years (n=24), 40-60 years (n=14), <40 years (n=18) 194 showed that anti-Spike antibody EPTs were significantly different between the age groups

001). Patients >60 years of age had higher anti-Spike antibody EPTs 196 compared to the 40-60-year-old group (Kruskal-Wallis test

Examination of the anti-Spike antibody classes and IgG subtypes 199 revealed significant difference between the age groups

and significantly higher IgG3 in the >60 year group when compared 202 to 40-60 year old group (Kruskal-Wallis test, p = 0.007). The anti-Spike IgG2 and IgG4 levels were not 203 significantly different (Fig 3C) and there was no significant difference in Spike p-score or RBD p-score 204 between the different age groups (Fig 3D-E). Interestingly, neuralisation titers were significantly 205 different among the age groups

Supplementary Fig 2A-C). However, 209 neutralisation was significantly higher among males compared to females

Anti-Spike endpoint titre was the most 215 important variable that predicted the Spike p-score (change in R 2 = 0.2277) (Table 2), while the rest of 216 the variables are listed in descending order of predictive value in Table 2. A parameter covariance matrix 217 was plotted to determine the associative relationships between the non-categorical independent variable 218 to yield the dependent variable Spike p-score, revealing that anti-Spike IgG1 and IgG3 associated 225 0.0001), and neutralisation titre

Although neutralisation titre significantly correlated with anti-Spike EPT (Spearman's r = 0.64, p = 227 0.0001) and anti-RBD EPT (Spearman's r = 0.34, p = 0.009) (Fig 5C-D)

Stratification of patient group by disease severity indicated that patients with moderate disease had the 229 most significant correlation of the Spike p-score to the anti-Spike EPTs (Spearman r = 0.71, p = 0.001), 230 and to the neutralisation titre

0005), as well as with anti-RBD EPT 234 (Spearman's r = 0.6, p = 0.01), while a negative but significant correlation with DPS was observed 235 (Spearman's r = -0.6, p = 0.007) (Figs 5C and 5F)

Spike p-score and anti-Spike EPT across the age groups (Fig 6B-C). Interestingly, only in the

year-old group, a significant correlation was observed between the neutralisation titre and anti-RBD EPT

Further longitudinal study of nine convalescent patients showed a significant decline of anti-Spike IgG

The anti-Spike EPT significantly decreased from visit 247 1 to visit 3 (Friedmann test, visit 1-visit 3, p = 0.0001) (Fig 7A). Similarly, the Spike p-score significantly 248 decreased from visit 1 to visit 3 (Friedmann test, visit 1-visit 3, p = 0.001) (Fig 7B). The neutralisation 249 titre also decreased significantly from visit 1 to visit 3 (Friedmann test

Although the anti-Spike EPT declined by an average of 91.2% (standard error of mean (SEM): 1.43) 251 from visit 1 to visit 3, there was better maintenance of the Spike p-score and neutralisation titre, which 252 showed 65.3% ± 9

Interestingly, the surface plasmon resonance studies showed up to 840-fold increase in the affinity (K D ) 254 of the anti-Spike antibodies to Spike protein in 8/9 patient plasma samples (mean = 150-fold increase

3-836.8) (Fig 7E-F). Conversely, the binding avidity (K d ) showed a significant decline

Central Adelaide Health Network (CALHN) were used in this study. Plasma was collected on days 10-264 94 post symptom onset

Buffy coats from 271 3 healthy donors obtained from the Australian Red Cross (material transfer agreement # 18-01NSW-272 06) were used as a source of blood monocytes for in vitro differentiation of primary macrophages

The study protocol was approved by the Human Research Ethics Committees of the Northern

Approval No. 13050), and the 279 Women's and Children's Health Network Human Research Ethics

Australia which was conducted according to the Declaration of Helsinki and International 281 Conference on Harmonization Good Clinical Practice

The monocytic cell line, THP-1 was obtained from ATCC 202 TIB

10% Fetal bovine serum, 0.05mM β-286 mercaptoethanol, 10mM HEPES and 100U/mL Penicillin-Streptomycin (Thermofisher Scientific, USA) 287 and passaged every two days. Expression of surface Fc-receptors was assessed by flow cytometry using 288 monoclonal antibodies (mAbs) against Fcγ receptor RI (CD64)-FITC, FcγRIII (CD16)-PE

After a one hour incubation in a 295 humidified 37°C incubator with 5% CO 2 air, non-adherent cells were removed by washing wells twice 296 with pre-warmed PBS and the adherent monocytes (~1x10 4 /well) were differentiated into 297 macrophages for six days using 50ng/mL granulocyte-macrophage colony-stimulating factor and 298 25ng/mL interleukin

Biotinylated recombinant SARS-CoV-2 Spike and RBD proteins 300 SARS-CoV-2 Wuhan-Hu-1 (GenPept: QJE37812) RBD protein (amino acid residues 319-541) and

Spike protein (amino acid residue 15-1213) were cloned into pCEP4 mammalian expression vector 302 containing N-terminal human Ig kappa leader sequence and C-terminal Avi-tag and His-tag 303

Vivaspin centrifugal concentrator (Sartorius, Germany) and stored at -80 °C. The Spike and RBD 312 recombinant proteins were then biotinylated via the C-terminal Avi-tag using a labelling kit 313 following the manufacturer's instructions

Endpoint titre and Isotyping of anti-SARS-CoV-2 Spike and anti-RBD antibodies in sera of 315 patients with SARS-CoV-2 infection

Anti-SARS-CoV-2 Spike and RBD IgG antibody in sera was quantified using a modified direct ELISA

Nunc immuno-microtiter plates were coated with 250ng of the recombinant SARS-CoV-2

14 wash buffer, plates were washed once, and serially diluted serum (in 5% skim milk) was added to each 322 well in duplicate

For the endpoint titre of total anti-Spike or anti-RBD antibodies, 50µL of horseradish peroxidase (HRP)-324 conjugated mouse anti-human detection antibody added per well (Jackson ImmunoResearch, USA) 325 (1:5000 dilution in 5% skim milk). For isotyping of the anti-Spike or anti-RBD antibodies, 50µL/well of 326 HRP-conjugated immunoglobulin subtype or IgG subclass specific detection antibodies were added

1:3000 dilution of 328 anti-human IgA (α-chain-specific) (Sigma) or 1:3000 dilution of anti-human IgM (μ-chain-specific) 329 (Sigma) antibody subtypes and 1:6000 dilution of anti-human IgG1, IgG2, IgG3 or IgG4 (Southern 330 Biotech, USA)

SARS-CoV-2 Spike or RBD protein coating and opsonisation of microbeads PBS and gentle centrifugation at 2292xg for five minutes

Aliquots (50µL) of the SARS-CoV-2 Spike or RBD coated beads were then opsonised for two hours 342 at 37ºC with 10µL of plasma obtained from patients with SARS-CoV-2 infection, or from healthy 343 control donors, and used immediately in the antibody dependent cellular phagocytosis assay. tube, mixed by gentle tapping

A total of 2x10 4 events were acquired and the proportions of cells that phagocytosed 352 the beads (% of cells that took up the beads) and their fluorescent intensities (amounts of beads taken 353 up per cell) were analysed using BD FlowJo version 10.5.0 software. Phagocytic scores (p-score) were 354 then calculated based on the proportion of cells that took up the opsonised beads

Cells incubated with Spike-or RBD protein-coated microbeads opsonised with plasma from via Fc-receptor (antibody-dependent), and other heat labile opsonins such as complements 361 (eg C3b), either the Fc-receptors on the THP-1 cells were pre-blocked using the universal Fc receptor 362 blocking agent

) coated glass cover slips were rinsed with PBS, resuspended in RPMI 1640 367 containing 0.1% human serum and 100mM HEPES and incubated with the Alexa-488 conjugated 368 opsonised microbeads for two hours at 37ºC, 5% CO 2 . Cells were then washed twice with cold PBS 369 containing 0.5% FBS and 0.005% sodium azide, fixed with 1% paraformaldehyde for five minutes at 370 room temperature, and rinsed twice with PBS. The fixed cells were blocked with 1% BSA in PBS, 371 incubated with 1:1000 dilution of Alexa-555-conjugated Phalloidin (Sigma, USA) for 30 minutes at room 372 temperature

Argon ion 488 nm (Alexa-488) and DPSS 561 nm 375 (Alexa-555 phalloidin) laser excitation sources, emitted light was filtered using combination of emission 376 filters and imaged onto Airy detector array producing an effective lateral resolution of ~100 nm

SARS-CoV-2 pseudovirus neutralisation assay

CoV-2 Spike pseudovirus were generated in 293T cells by co-transfecting 380 expression plasmids containing SARS-CoV-2 Spike and MLV gag/pol and luciferase vectors using 381 Calphos transfection kit (Takara Bio, USA) as described [20]. post transfection, concentrated 10-fold using 100,000 MWCO 383 Vivaspin centrifugal concentrators (Sartorius, Germany) and used for neutralisation assays. Briefly, 384 pseudovirus were incubated for one hour with heat inactivated (56 °C for 30 minutes) patient serum 385 prior to infecting 293T-ACE2 cells

Infected cells were incubated at 37°C in a humidified incubator with 5% CO 2 , replenished with 388 fresh media, further incubated for 72 hours, and then lysed with a lysis buffer

Relative Luminescence Unit (RLU) in cell lysates was measured using CLARIOstar microplate 390 reader (BMG Labtech, Australia), percentage neutralisation of Spike pseudovirus determined and 391 the fifty percent inhibitory (ID50) calculated using non-linear regression model

USA) to determine the 396 binding characteristics of the anti-Spike polyclonal antibodies in patient plasma to SARS-CoV-2 Spike 397 antigen. Briefly, 10µg/mL of C-terminal 6X-His tag containing recombinant SARS-CoV-2 Spike protein immobilised with anti-His mAb using EDC/NHS amine coupling kit

The sensor chips were equilibrated with running buffer

:100) in the running 403 buffer were then injected over the immobilised flow cells at a rate of 20 µl/min for 120 s at 25°C. After 404 each patient plasma, then chip was regenerated using 10 mM glycine, pH 2 (Cytiva, USA) for 60 blank injection (zero analyte concentration). Kinetic constants

All data were analysed with Prism Software (version 9.0, GraphPad, USA)

To test the difference 17 413 between three or more groups, parametric ANOVA or Kruskal-Wallis test followed by Dunn's test was 414 used, where appropriate, based on the distribution of the residual plot. Spearman's correlation was used 415 to compare Spike and RBD

Friedman's test with pairwise Dunn's tests were used to compare the repeated measures of Spike

Spike and RBD end point titre, neutralisation titre and antibody affinity across the timepoints V1, V2 418 and V3

To rank the variables of statistical importance that associated with Spike p-score (dependent variable), 420 multiple linear regression analysis was performed using disease severity, age, gender

This change in R 2 represents the amount of unique 424 variance that each variable explains that the other variables in the model cannot explain. A parameter 425 covariance matrix was then used to plot the associative relationships between the independent variable 426 using the standardised beta coefficient, where a score above one is considered a positive relationship, of disease severity and anti-Spike end point antibody titers. COVID-19 disease severity was 432 also found to be associated with increased phagocytic responses in patients that recovered from COVID-433 19 disease. Importantly also, this report reveals for the first time that affinity of anti-Spike antibodies in 434 convalescent patient samples increased over the 12-month

By contrast, in this 440 study, native patient plasma was used revealing that the early phagocytic response in SARS-CoV-2 441 infection is primarily driven by heat labile components in the plasma, along with a contribution from Fc-442 receptor dependent antibody functions. Further, the studies revealed that samples from acutely ill patients 443 may have significant anti-Spike antibody mediated phagocytosis activity, despite having undetectable 444 antibody titers. These findings suggest that like other respiratory viral infections, the most important heat 445 labile components of plasma contributing to viral phagocytosis are the classically activated complement 446 products that upon interaction with complement-fixing IgM and IgG1 can lead to enhanced phagocytosis 447 through interactions with Fc and complement receptors

There is ample evidence to support the association between complement activation through the classical, 450 lectin and alternate pathways and clinical severity in COVID-19, including strong links to worsened 451 disease severity and systemic inflammation

Interestingly, it has also been shown that anti-Spike tissue injury [32]. Our finding that blocking of the Fc-receptors can only partially abrogate the 454 phagocytic response

Fc-receptor specific antibody functions. Enhancement of phagocytosis by complement may trigger Fc-456 receptor-and complement receptor-mediated excessive activation of phagocytic effector cells leading to

This collaborative response may also contribute to more effective viral elimination leading to the 459 sometimes favourable clinical outcome, as observed by Federica et al

Multiple regression 464 analysis showed that the most important variable related to a high phagocytic response was anti-Spike 465 antibody endpoint titre. Further, older patients mounted significantly higher neutralisation activity and 466 had higher antibody endpoint titers, while gender had little impact on the phagocytic function. These 467 results are consistent with recent studies in which disease severity and age were identified as major 468 contributors to endpoint antibody titers and their neutralisation functions

While the progressive decline of the antibody titers is consistent with previous studies 479 [35-37], the data presented here show for the first time, a significant increase in the anti-Spike antibody 480 affinity over time, which may have contributed to the retention of the effector functions despite the decay 481 of the endpoint titers to baseline. This finding concurs with longitudinal B cell studies that have reported 482 ongoing affinity maturation and improved affinity of SARS-Cov-2 specific memory B

first study to demonstrate antibodies in the circulation 484 showing functional improvement correlating with the functional characteristics observed in memory B 485 cells. These new results have potential clinical implications. They challenge current clinical practice that 486 considers measurement of the anti-Spike antibody titers but not their quality as one of the gold standard

Coordinating principal investigator), Marianne Martinello (Co-ordinating principal investigator), Marianne Byrne (Clinical Trials Manager), Mohammed Hammoud (Post-Doctoral Fellow and Data Manager

Adam Bartlett (Sydney Children's Hospital

Katerina Mitsakos (RNSH)

Research reported in this publication was supported by Snow Medical Foundation as an investigator-initiated study. The content is solely the responsibility of the authors. RAB, MM, CR (grant No. 1173666) and ARL (No. 1137587) are Fellows funded by National Health and

COVID-19 Map -Johns Hopkins Coronavirus Resource Center

Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science (80-)

Antibody potency, effector function, and combinations in protection and therapy for SARS-cov-2 infection in vivo

DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science (80-)

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus

Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality

Biological and clinical factors contributing to the metabolic heterogeneity of hospitalized patients with and without covid-19

Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19. Front Immunol

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Broad autoreactive IgM responses are common in critically ill patients

Decay of Fcdependent antibody functions after mild to moderate COVID-19

Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs

The Influence of the Lectin Pathway of Complement Activation on Infections of the Respiratory System

New South Wales Health. NSW COVID-19 data | Data

Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection

COVID-19 treatment NIH. Clinical Spectrum | COVID-19 Treatment Guidelines

Establishment and characterization of a human acute monocytic leukemia cell line (THP-1)

Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection

Culture of Macrophage Colony-stimulating Factor Differentiated Human Monocyte-derived Macrophages

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers

A statistically defined endpoint titer determination method for immunoassays

The effect of heat inactivation of serum on aggregation of immunoglobulins

Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials. medRxiv Prepr Serv Heal Sci

neurite outgrowth and synapses formation through a high-affinity interaction with Nogo 66

Dissecting antibody-mediated protection against SARS-CoV-2

COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions." mBio. Cold Spring Harbor Laboratory

Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv Prepr Serv Heal Sci

Systems serology detects functionally distinct coronavirus antibody features in children and elderly

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

Evidence for antibody as a protective correlate for COVID-19 vaccines

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

The authors would like to thank the study participants for their contribution to the research, as well as current and past researchers and staff. They would like to acknowledge members of the study group: 

The authors declare no competing interests.